Q&A with Immupharma (IMM) Chairman Tim McCarthy
Tim McCarthy, Chairman of discusses the deal with US-based Avion Pharmaceuticals, the agreement with Lanstead Capital and what the future holds for ImmuPharma regarding new trial design as well as anticipated upcoming milestones.
Mr. McCarthy said: “Avion have agreed to fully fund the phase 3 development through to registration and all the costs surrounding that up to $25 million. To put that in context, that's more than twice the amount we spent on the first phase 3 study”
Commenting on a new trial design he said: “What we are now doing is putting together a new design based on the lessons we learned from the first phase 3”
He said: “If we choose a particular profile of patients with a particular biomarker, then we will more than likely have a higher chance of success in terms of showing the efficacy.”
Follow News & Updates from ImmuPharma here:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.